Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BNTX BioNTech	$112.31 +0.5%	$103.17	$76.53 ▼ $131.49	$27.01B	1.29	941,700 shs	214,854 shs
ONC BeOne Medicines	$254.47 -0.5%	$247.35	$146.21 ▼ $287.88	$27.89B	0.28	434,353 shs	72,069 shs
TEVA Teva Pharmaceutical Industries	$16.63 -0.5%	$17.07	$12.47 ▼ $22.80	$19.08B	0.6	10.27 million shs	2.93 million shs
VRNA Verona Pharma PLC American Depositary Share	$104.96 +0.2%	$82.60	$16.91 ▼ $104.99	$8.51B	0.24	1.55 million shs	11.11 million shs

A Beginner's Guide to Investing in Cannabis

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BNTX BioNTech	+0.11%	+3.25%	+2.58%	+20.04%	+38.84%
ONC BeOne Medicines	+4.59%	+4.65%	-3.07%	+22.74%	+25,568,999,900.00%
TEVA Teva Pharmaceutical Industries	+0.42%	-2.05%	-7.47%	+30.17%	+5.82%
VRNA Verona Pharma PLC American Depositary Share	+20.62%	+16.31%	+23.78%	+94.27%	+514.85%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BNTX BioNTech	1.82 of 5 stars	3.4	2.0	2.6	0.8	0.0
ONC BeOne Medicines	3.3579 of 5 stars	4.5	0.0	2.4	1.7	0.6
TEVA Teva Pharmaceutical Industries	4.1997 of 5 stars	4.6	3.0	2.8	1.7	1.9
VRNA Verona Pharma PLC American Depositary Share	1.7442 of 5 stars	2.4	1.0	3.4	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BNTX BioNTech	2.83	Moderate Buy	$137.91	22.79% Upside
ONC BeOne Medicines	3.00	Buy	$320.67	26.01% Upside
TEVA Teva Pharmaceutical Industries	3.25	Buy	$24.71	48.64% Upside
VRNA Verona Pharma PLC American Depositary Share	2.69	Moderate Buy	$107.45	2.38% Upside

Current Analyst Ratings Breakdown

Latest VRNA, BNTX, ONC, and TEVA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/10/2025	BNTX BioNTech	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Overweight ➝ Overweight	$132.00 ➝ $133.00
7/10/2025	VRNA Verona Pharma PLC American Depositary Share	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$138.00 ➝ $107.00
7/10/2025	VRNA Verona Pharma PLC American Depositary Share	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral
7/9/2025	VRNA Verona Pharma PLC American Depositary Share	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold	$107.00
7/9/2025	VRNA Verona Pharma PLC American Depositary Share	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold	$140.00 ➝ $107.00
7/1/2025	VRNA Verona Pharma PLC American Depositary Share	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$170.00
6/27/2025	ONC BeOne Medicines	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$313.00 ➝ $330.00
6/27/2025	ONC BeOne Medicines	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$317.00 ➝ $321.00
6/27/2025	ONC BeOne Medicines	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform ➝ Moderate Buy	$311.00
6/26/2025	TEVA Teva Pharmaceutical Industries	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$24.00 ➝ $23.00
6/25/2025	BNTX BioNTech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$138.00

(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BNTX BioNTech	$2.75B	9.83	N/A	N/A	$87.61 per share	1.28
ONC BeOne Medicines	$3.81B	7.32	N/A	N/A	$34.10 per share	7.46
TEVA Teva Pharmaceutical Industries	$16.54B	1.15	$3.37 per share	4.94	$4.74 per share	3.51
VRNA Verona Pharma PLC American Depositary Share	$118.54M	71.79	N/A	N/A	$2.56 per share	41.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BNTX BioNTech	-$719.92M	-$3.40	N/A	N/A	N/A	-27.37%	-3.94%	-3.41%	8/4/2025 (Estimated)
ONC BeOne Medicines	-$644.79M	-$3.72	N/A	358.41	N/A	-9.40%	-7.55%	-4.42%	N/A
TEVA Teva Pharmaceutical Industries	-$1.64B	-$1.15	N/A	6.32	0.85	-7.74%	45.44%	6.95%	7/30/2025 (Estimated)
VRNA Verona Pharma PLC American Depositary Share	-$173.42M	-$2.00	N/A	3,498.50	N/A	N/A	-69.65%	-28.00%	8/6/2025 (Estimated)

Latest VRNA, BNTX, ONC, and TEVA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2025	Q2 2025	VRNA Verona Pharma PLC American Depositary Share	$0.39	N/A	N/A	N/A	$68.24 million	N/A
8/4/2025	Q2 2025	BNTX BioNTech	-$1.38	N/A	N/A	N/A	$161.26 million	N/A
7/30/2025	Q2 2025	TEVA Teva Pharmaceutical Industries	$0.64	N/A	N/A	N/A	$4.34 billion	N/A
5/7/2025	Q1 2025	ONC BeOne Medicines	-$0.71	$1.22	+$1.93	$0.01	$1.12 billion	$1.12 billion
5/7/2025	Q1 2025	TEVA Teva Pharmaceutical Industries	$0.47	$0.52	+$0.05	$0.18	$3.99 billion	$3.89 billion
4/29/2025	Q1 2025	VRNA Verona Pharma PLC American Depositary Share	-$0.22	$0.27	+$0.49	-$0.16	$41.47 million	$98.65 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BNTX BioNTech	$1.53	1.36%	N/A	N/A	N/A
ONC BeOne Medicines	N/A	N/A	N/A	N/A	N/A
TEVA Teva Pharmaceutical Industries	N/A	N/A	N/A	N/A	N/A
VRNA Verona Pharma PLC American Depositary Share	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BNTX BioNTech	0.01	10.18	10.02
ONC BeOne Medicines	0.05	1.96	1.71
TEVA Teva Pharmaceutical Industries	2.59	1.03	0.74
VRNA Verona Pharma PLC American Depositary Share	1.07	8.86	8.73

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BNTX BioNTech	15.52%
ONC BeOne Medicines	48.55%
TEVA Teva Pharmaceutical Industries	54.05%
VRNA Verona Pharma PLC American Depositary Share	85.88%

Insider Ownership

Company	Insider Ownership
BNTX BioNTech	19.20%
ONC BeOne Medicines	6.62%
TEVA Teva Pharmaceutical Industries	0.49%
VRNA Verona Pharma PLC American Depositary Share	4.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BNTX BioNTech	6,772	240.39 million	194.24 million	Optionable
ONC BeOne Medicines	11,000	109.60 million	102.34 million	N/A
TEVA Teva Pharmaceutical Industries	36,830	1.15 billion	1.14 billion	Optionable
VRNA Verona Pharma PLC American Depositary Share	30	81.08 million	81.05 million	Optionable

VRNA, BNTX, ONC, and TEVA Headlines

Recent News About These Companies

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) Sees Large Volume Increase - Here's Why

1 hour ago | marketbeat.com

Merck to buy Verona Pharma for USD 10 billion

2 hours ago | medicaldialogues.inM

Jefferies Downgrades Verona Pharma plc - Depositary Receipt () (VRNA)

2 hours ago | msn.com

Verona Pharma (VRNA) Skyrockets 20.6% on $10-Billion Merger Deal with Merck

2 hours ago | msn.com

Verona Pharma PLC American Depositary Share's (VRNA) "Equal Weight" Rating Reaffirmed at Wells Fargo & Company

4 hours ago | marketbeat.com

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) Receives Neutral Rating from BTIG Research

5 hours ago | marketbeat.com

Verona Pharma Stock Soars to All-Time High as Merck Buys Firm for $10B

July 9 at 7:58 PM | msn.com

Verona Pharma leaps on news of Merck & Co takeover bid

July 9 at 7:58 PM | thepharmaletter.comT

Merck confirms $10B buyout of Verona Pharma

July 9 at 7:58 PM | msn.com

Merck to Acquire Verona Pharma in $10 Billion Deal to Expand Respiratory Drug Portfolio

July 9 at 7:58 PM | msn.com

Top Mid Cap Stocks To Add to Your Watchlist - July 9th

July 9 at 4:36 PM | marketbeat.com

Promising Pharmaceutical Stocks To Watch Now - July 9th

July 9 at 4:36 PM | marketbeat.com

Top Medical Stocks Worth Watching - July 9th

July 9 at 4:36 PM | marketbeat.com

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) Given "Hold" Rating at Canaccord Genuity Group

July 9 at 4:26 PM | marketbeat.com

Verona Pharma PLC American Depositary Share's (VRNA) Hold Rating Reaffirmed at Jefferies Financial Group

July 9 at 4:26 PM | marketbeat.com

VRNA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Verona Pharma plc Is Fair to Shareholders

July 9 at 12:07 PM | businesswire.com

Merck Buys Verona Pharma: A Good Deal, But M&A Spree Must Continue

July 9 at 11:59 AM | seekingalpha.com

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) Sets New 52-Week High - Should You Buy?

July 9 at 10:54 AM | marketbeat.com

Verona Pharma Stock Jumps 20% on $10B Buyout Offer From Merck

July 9 at 10:20 AM | zacks.com

Verona Pharma Stock Jumps 21%. It's Being Bought for $10 Billion by Merck.

July 9 at 7:14 AM | barrons.com

Merck to Acquire Verona Pharma, Expanding its Portfolio to Include OhtuvayreÂ® (ensifentrine), a First-In-Class COPD Maintenance Treatment for Adults and Expected to Drive Growth into the Next Decade

July 9 at 7:02 AM | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
D-Wave Is Rising Again Despite Dilution—What’s the Deal?
By Nathan Reiff | July 7, 2025
View D-Wave Is Rising Again Despite Dilution—What’s the Deal?
RKLB Breakout Fails Near Highs: Should Investors Be Concerned?
By Ryan Hasson | June 11, 2025
View RKLB Breakout Fails Near Highs: Should Investors Be Concerned?
IGM ETF: Expand Tech Exposure With Top AI Leaders
By Jeffrey Neal Johnson | July 1, 2025
View IGM ETF: Expand Tech Exposure With Top AI Leaders

VRNA, BNTX, ONC, and TEVA Company Descriptions

BioNTech NASDAQ:BNTX

$112.31 +0.53 (+0.48%)

As of 12:44 PM Eastern

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

BeOne Medicines NASDAQ:ONC

$254.47 -1.22 (-0.48%)

As of 12:20 PM Eastern

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

Teva Pharmaceutical Industries NYSE:TEVA

$16.63 -0.08 (-0.50%)

As of 12:44 PM Eastern

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

Verona Pharma PLC American Depositary Share NASDAQ:VRNA

$104.96 +0.19 (+0.18%)

As of 12:44 PM Eastern

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time